Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

0.86DKK
27 Mar 2015
Change (% chg)

-- (--)
Prev Close
kr.0.86
Open
kr.0.87
Day's High
kr.0.88
Day's Low
kr.0.85
Volume
407,086
Avg. Vol
1,361,965
52-wk High
kr.2.30
52-wk Low
kr.0.82

VELOX.CO

Chart for VELOX.CO

About

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a Denmark-based company active in the biotechnology and pharmaceutical industry. It is primarily focused on the development of its transplant immunosuppression product candidate, LCP-Tacro. LCP-Tacro is being developed as a once-daily dosage version of tacrolimus for... (more)

Overall

Beta: 0.17
Market Cap(Mil.): kr.1,430.18
Shares Outstanding(Mil.): 1,663.00
Dividend: --
Yield (%): --

Financials

  VELOX.CO Industry Sector
P/E (TTM): -- 132.14 40.89
EPS (TTM): -0.02 -- --
ROI: -13.65 -0.52 16.10
ROE: -13.65 -2.20 16.95
Search Stocks

BRIEF-Veloxis Pharmaceuticals 2014 operating loss narrows to DKK 58.6 million

* 2014 revenue 123.4 million Danish crowns ($18.49 million) versus 38.1 million crowns year ago

03 Mar 2015

BRIEF-Veloxis confirms receipt of U.S. FDA decision

* Veloxis confirms receipt of U.S. Food and Drug Administration (FDA) decision

13 Jan 2015

BRIEF-Veloxis Announces Publication of Phase III Study of Once Daily Envarsus XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients

* Veloxis Announces Publication of Phase III Study of Once Daily Envarsus XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients Source text for Eikon: Further company coverage: (gdynia.newsroom@thomsonreuters.com; +48 58 698 3920)

17 Nov 2014

BRIEF-Veloxis announces tentative approval of Envarsus XR

* FDA states that approval will not be final until Astagraf XL exclusivity expires

31 Oct 2014

BRIEF-Cegedim Relationship Management CRM and support services implemented by Veloxis Pharmaceuticals

* Says Veloxis Pharmaceuticals is implementing Cegedim Relationship Management mobile intelligence customer relationship management (CRM) and support services for their Medical Science Liaison (MSL) and Specialty teams Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20; Gdynia.newsroom@thomsonreuters.com)

14 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks